Author:
Lankheet N A G,Kloth J S L,Gadellaa-van Hooijdonk C G M,Cirkel G A,Mathijssen R H J,Lolkema M P J K,Schellens J H M,Voest E E,Sleijfer S,de Jonge M J A,Haanen J B A G,Beijnen J H,Huitema A D R,Steeghs N
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003a) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471–478.
2. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK (2003b) Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2: 1011–1021.
3. Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, Rodrigues MJ, Rousseau B, Blanchet B, Goldwasser F (2012) Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs 30: 2046–2049.
4. Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY (2012) Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 118: 1252–1259.
5. Beumer JH (2013) Without therapeutic drug monitoring, there is no personalized cancer care. Clin Pharmacol Ther 93: 228–230.
Cited by
86 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献